Alnylam Pharmaceuticals (ALNY) Rating Increased to Hold at Zacks Investment Research

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Alnylam reported positive data from the ATLAS study which led to regulatory filings for its late-stage pipeline candidate patisiran and an action date of Aug 11, 2018 as set by the FDA. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020. Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company. Stiff competition remains a threat as well. Estimates have remained stable ahead of the Q1 earnings results.”

How to Become a New Pot Stock Millionaire

Other research analysts also recently issued reports about the stock. BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, March 14th. Piper Jaffray restated a “buy” rating and set a $182.00 target price on shares of Alnylam Pharmaceuticals in a research report on Sunday, January 7th. Jefferies Group set a $156.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, February 9th. BMO Capital Markets decreased their target price on shares of Alnylam Pharmaceuticals from $165.00 to $160.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. Finally, Evercore ISI began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 28th. They set a “line” rating and a $143.00 target price for the company. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $134.15.

Shares of NASDAQ:ALNY traded up $2.16 on Tuesday, hitting $98.00. 619,716 shares of the company were exchanged, compared to its average volume of 1,005,522. Alnylam Pharmaceuticals has a 1-year low of $49.14 and a 1-year high of $153.99. The company has a current ratio of 12.23, a quick ratio of 12.23 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $10,093.27, a P/E ratio of -18.09 and a beta of 2.68.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. The company had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. The company’s quarterly revenue was up 116.6% on a year-over-year basis. equities analysts forecast that Alnylam Pharmaceuticals will post -7.02 EPS for the current year.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 38,460 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, March 14th. The shares were sold at an average price of $143.10, for a total value of $5,503,626.00. Following the completion of the transaction, the president now owns 97,544 shares of the company’s stock, valued at $13,958,546.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Laurie Keating sold 20,000 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $145.00, for a total transaction of $2,900,000.00. Following the completion of the transaction, the senior vice president now directly owns 24,500 shares of the company’s stock, valued at approximately $3,552,500. The disclosure for this sale can be found here. Insiders sold 198,620 shares of company stock valued at $28,404,143 in the last ninety days. 3.70% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its stake in shares of Alnylam Pharmaceuticals by 16.4% during the fourth quarter. BlackRock Inc. now owns 7,115,063 shares of the biopharmaceutical company’s stock worth $903,969,000 after purchasing an additional 1,003,366 shares in the last quarter. UBS Asset Management Americas Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2.2% during the fourth quarter. UBS Asset Management Americas Inc. now owns 1,394,213 shares of the biopharmaceutical company’s stock worth $177,135,000 after purchasing an additional 29,816 shares in the last quarter. Gilder Gagnon Howe & Co. LLC increased its stake in shares of Alnylam Pharmaceuticals by 8.6% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 1,217,367 shares of the biopharmaceutical company’s stock worth $154,666,000 after purchasing an additional 96,812 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 13.4% during the fourth quarter. Geode Capital Management LLC now owns 747,646 shares of the biopharmaceutical company’s stock worth $94,929,000 after purchasing an additional 88,119 shares in the last quarter. Finally, Bridger Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 30.3% during the fourth quarter. Bridger Management LLC now owns 500,219 shares of the biopharmaceutical company’s stock worth $63,553,000 after purchasing an additional 116,286 shares in the last quarter. 92.00% of the stock is owned by institutional investors.

WARNING: This news story was originally published by registrarjournal.com and is owned by of registrarjournal.com. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://registrarjournal.com/2018/04/17/alnylam-pharmaceuticals-alny-rating-increased-to-hold-at-zacks-investment-research.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply